Halobetasol Propionate Foam vs Halobetasol Propionate Lotion

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline

Halobetasol Propionate Foam · Lexette

Rights held by Mayne Pharma; US product discontinued

Approved in Psoriasissmall molecule
Reliable signal

NCT02742441 · Phase 3 · completed

The trial randomized 409 participants to active foam or vehicle foam and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was met, with treatment success in 30.7% versus 7.4% of participants at Day 15 (p<0.001).

Reported efficacy

Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4% (met)

Result source: NCT02742441

Halobetasol Propionate Lotion · Bryhali

Marketed by Bausch Health

Approved in Psoriasissmall molecule
Partial signal

NCT02514577 · Phase 3 · completed

The study was randomized, quadruple-blinded and vehicle-controlled, with 217 participants, and used a clinical Investigator's Global Assessment treatment-success endpoint at Week 8. The peer-reviewed report of the two Phase 3 trials states superiority over vehicle at Week 8 (36.5% (Study 1) vs vehicle, P<0.001), so the primary comparison was met.

Reported efficacy

Percentage of Participants With Treatment Success at Week 8: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13% (met)

Result source: NCT02514577

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHalobetasol Propionate FoamHalobetasol Propionate Lotion
PASI 75—Not posted · NCT02367911—Not reported
PASI 90—Not posted · NCT02367911—Not reported
PASI 100—Not posted · NCT02367911—Not reported
sPGA 0/1—Not posted · NCT0236791136.5% vs 8.1%+28.4 vs placebowk 8 · n 143NCT02514577
9 other results
  • 38.4% vs 12.0% wk 8 · n 142 · Phase 3 · primary NCT02515097
  • 19.5% vs 6.7% wk 12 · n 143 · Phase 3 · secondary NCT02514577
  • 23.0% vs 9.3% wk 12 · n 142 · Phase 3 · secondary NCT02515097
  • 30.1% vs 7.9% wk 6 · n 143 · Phase 3 · secondary NCT02514577
  • 27.7% vs 4.3% wk 6 · n 142 · Phase 3 · secondary NCT02515097
  • 19.8% vs 2.8% wk 4 · n 143 · Phase 3 · secondary NCT02514577
  • 19.3% vs 0.2% wk 4 · n 142 · Phase 3 · secondary NCT02515097
  • 7.1% vs 0% wk 2 · n 143 · Phase 3 · secondary NCT02514577
  • 4.9% vs 0% wk 2 · n 142 · Phase 3 · secondary NCT02515097
DLQI, change—Not posted · NCT02367911—Not reported

PASI 75

Halobetasol Propionate Foam
—Not posted · NCT02367911
Halobetasol Propionate Lotion
—Not reported

PASI 90

Halobetasol Propionate Foam
—Not posted · NCT02367911
Halobetasol Propionate Lotion
—Not reported

PASI 100

Halobetasol Propionate Foam
—Not posted · NCT02367911
Halobetasol Propionate Lotion
—Not reported

sPGA 0/1

Halobetasol Propionate Foam
—Not posted · NCT02367911
Halobetasol Propionate Lotion
36.5% vs 8.1%+28.4 vs placebowk 8 · n 143NCT02514577
9 other results
  • 38.4% vs 12.0% wk 8 · n 142 · Phase 3 · primary NCT02515097
  • 19.5% vs 6.7% wk 12 · n 143 · Phase 3 · secondary NCT02514577
  • 23.0% vs 9.3% wk 12 · n 142 · Phase 3 · secondary NCT02515097
  • 30.1% vs 7.9% wk 6 · n 143 · Phase 3 · secondary NCT02514577
  • 27.7% vs 4.3% wk 6 · n 142 · Phase 3 · secondary NCT02515097
  • 19.8% vs 2.8% wk 4 · n 143 · Phase 3 · secondary NCT02514577
  • 19.3% vs 0.2% wk 4 · n 142 · Phase 3 · secondary NCT02515097
  • 7.1% vs 0% wk 2 · n 143 · Phase 3 · secondary NCT02514577
  • 4.9% vs 0% wk 2 · n 142 · Phase 3 · secondary NCT02515097

DLQI, change

Halobetasol Propionate Foam
—Not posted · NCT02367911
Halobetasol Propionate Lotion
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Halobetasol Propionate Foam: 6 of 6 rows · Halobetasol Propionate Lotion: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricHalobetasol Propionate Foam
Rows use multiple source trials
Halobetasol Propionate Lotion
BSA
absolute change · percentage points
Induction
-1.5% (n=199) vs -0.2% (n=196) placebo @ 2.14wka,b,c
NCT02742441 · Phase 3
1 other source trial
-1.3% (n=23) vs 0% (n=20) placebo @ 2.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence
-1.3% (n=36) vs -0.2% (n=35) placebo @ 2.14wk0.05% lotiona,b,c
NCT01610596 · Phase 2 · registry result, not featured evidence
PGA 2-point Improvement
responder rate · % of participants
Induction
52.2% (n=23) vs 0% (n=20) placebo @ 2.14wkb,c
NCT01700985 · Phase 2 · registry result, not featured evidence
44.4% (n=36) vs 0% (n=35) placebo @ 2.14wk0.05% lotionb,c
NCT01610596 · Phase 2 · registry result, not featured evidence
Dropout rate
2.9%d
NCT02742441 · Phase 3
show 4 more results
1.3%
NCT02368210 · Phase 3
7%
NCT02367911 · Phase 3
0%
NCT01698333 · Phase 2 · registry result, not featured evidence
0%
NCT01700985 · Phase 2 · registry result, not featured evidence
9.8%e
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
4.9%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
0%0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%d
NCT02742441 · Phase 3
show 4 more results
0%
NCT02368210 · Phase 3
—
NCT02367911 · Phase 3
—
NCT01698333 · Phase 2 · registry result, not featured evidence
—
NCT01700985 · Phase 2 · registry result, not featured evidence
0.7%e
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
1.4%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
—0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Serious AEs
0%d
NCT02742441 · Phase 3
show 4 more results
0%
NCT02368210 · Phase 3
0%
NCT02367911 · Phase 3
0%
NCT01698333 · Phase 2 · registry result, not featured evidence
0%
NCT01700985 · Phase 2 · registry result, not featured evidence
0.7%e
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
1.4%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
0%0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
d
headache 1.5% (placebo 1.5%)
application site pain 1% (placebo 0.5%)
back pain 0.5% (placebo 0%)
NCT02742441 · Phase 3
show 4 more results
abdominal pain 1.3% (placebo 0%)
application site pain 1.3% (placebo 0%)
hordeolum 1.3% (placebo 0%)
NCT02368210 · Phase 3
sinusitis 1.4% (placebo 0%)
trichorrhexis 1.4% (placebo 0%)
application site dryness 0% (placebo 1.4%)
NCT02367911 · Phase 3
acth stimulation test abnormal 24%
nasal congestion 4%
pharyngitis 4%
NCT01698333 · Phase 2 · registry result, not featured evidence
influenza like illness 4.3% (placebo 0%)
pharyngitis 0% (placebo 4.8%)
upper respiratory tract infection 0% (placebo 9.5%)
NCT01700985 · Phase 2 · registry result, not featured evidence
0.05% lotione
application site pain 8.3% (placebo 8.3%)
application site atrophy 5.6% (placebo 0%)
application site discoloration 2.8% (placebo 0%)
NCT01610596 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Halobetasol Propionate Foam

IGA "Treatment Success 30.7% (n=205) vs 7.4% (n=204) placebo @ 2.14wk
responder rate · % of participants
NCT02742441 · Phase 3
show 2 more results
9.5% (n=199) vs 3.6% (n=196) placebo @ 1.14wk
NCT02742441 · Phase 3
18.3% (n=71) vs 9.6% (n=73) placebo @ 2.14wk
NCT02367911 · Phase 3
Scaling 33.7% (n=205) vs 9.8% (n=204) placebo @ 2.14wk
responder rate · % of participants
Scaling
NCT02742441 · Phase 3
show 4 more results
14.2% (n=205) vs 3.6% (n=204) placebo @ 1.14wk
Scaling
NCT02742441 · Phase 3
28% (n=75) vs 5.3% (n=76) placebo @ 2.14wk
Scaling
NCT02368210 · Phase 3
12.2% (n=75) vs 3.9% (n=76) placebo @ 1.14wk
Scaling
NCT02368210 · Phase 3
32.4% (n=71) vs 13.7% (n=73) placebo @ 2.14wk
Scaling
NCT02367911 · Phase 3
Pruritus -4.3 vs -2.5 placebo score @ 2.14wk
absolute change · score
NCT02742441 · Phase 3
show 1 more result
-4.4 vs -2 placebo score @ 2.14wk
NCT02368210 · Phase 3
IGA 25.3% (n=75) vs 3.9% (n=76) placebo @ 2.14wk
responder rate · % of participants
NCT02368210 · Phase 3
show 1 more result
8.1% (n=75) vs 2.6% (n=76) placebo @ 1.14wk
NCT02368210 · Phase 3
BSA -0.9% (n=75) vs -0.2% (n=76) placebo @ 2.14wk
absolute change · percentage points
Change in % BSA at Day 15
NCT02368210 · Phase 3
PGA 52.2% (n=23) vs 0% (n=20) placebo @ 2.14wk
absolute change · percentage points
NCT01700985 · Phase 2 · registry result, not featured evidence
PGA 0% (n=23) vs 0% (n=20) placebo @ 1.14wk
responder rate · % of participants
NCT01700985 · Phase 2 · registry result, not featured evidence
show 1 more result
52.2% (n=23) vs 0% (n=20) placebo @ 2.14wk
NCT01700985 · Phase 2 · registry result, not featured evidence

Halobetasol Propionate Lotion

sPGA 0/1 36.5% (n=143) vs 8.13% (n=74) placebo @ 8wk
responder rate · % of participants
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 9 more results
7.06% (n=143) vs 0% (n=74) placebo @ 2wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
19.81% (n=143) vs 2.77% (n=74) placebo @ 4wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
30.14% (n=143) vs 7.93% (n=74) placebo @ 6wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
19.48% (n=143) vs 6.69% (n=74) placebo @ 12wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
38.41% (n=142) vs 11.99% (n=71) placebo @ 8wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
4.93% (n=142) vs 0% (n=71) placebo @ 2wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
19.26% (n=142) vs 0.2% (n=71) placebo @ 4wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
27.71% (n=142) vs 4.35% (n=71) placebo @ 6wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
23.04% (n=142) vs 9.34% (n=71) placebo @ 12wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
PGA 0-1 30.6% (n=36) vs 0% (n=35) placebo @ 2.14wk0.05% lotion
responder rate · % of participants
NCT01610596 · Phase 2 · registry result, not featured evidence
Scaling 25% (n=36) vs 8.6% (n=35) placebo @ 1.14wk0.05% lotion
responder rate · % of participants
Scaling (Day 8)
NCT01610596 · Phase 2 · registry result, not featured evidence
Scaling 61.1% (n=36) vs 11.4% (n=35) placebo @ 2.14wk0.05% lotion
responder rate · % of participants
Scaling (Day 15)
NCT01610596 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Halobetasol Propionate Foam's landscape · Halobetasol Propionate Lotion's landscape